Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ML141 (CID-2950007) 是一种高效变构,选择性可逆的 Cdc42 GTPase 非竞争性抑制剂,IC50值为200 nM。它抑制 Cdc42 野生型和 Cdc42 Q61L 突变体。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 235 | 现货 | ||
2 mg | ¥ 337 | 现货 | ||
5 mg | ¥ 578 | 现货 | ||
10 mg | ¥ 990 | 现货 | ||
25 mg | ¥ 1,870 | 现货 | ||
50 mg | ¥ 3,280 | 现货 | ||
100 mg | ¥ 4,850 | 现货 | ||
500 mg | ¥ 9,870 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 632 | 现货 |
产品描述 | ML141 (CID-2950007) is an effective, specific and reversible non-competitive inhibitor of Rho family GTPase cdc42 (IC50: 200 nM). |
靶点活性 | cdc42:200 nM |
体外活性 | 在负荷MDA-MB 231源肿瘤的NOD/SCID小鼠体内, ML141(1 mg/day,i.p.)通过抑制Cdc42可使TMX抑制MDA-MB 231衍生的肿瘤的生长.此外, ML141(10 mg/kg,i.p.)可增强小鼠体内粒细胞集落刺激因子诱导的造血干细胞和祖细胞动员. |
体内活性 | ML141对二甲双胍诱导的神经母细胞瘤凋亡损害具有明显的保护作用。通过对细胞死亡/分裂的诱导/抑制,ML141可使咖啡因抑制细胞生长的能力增强。ML141还可剂量依赖性减少肺炎克雷伯菌入侵。 |
激酶实验 | Equilibrium binding assay : Wild-type GST-Cdc42 (4 μM) is bound to GSH-beads overnight at 4°C. Cdc42 on GSH-beads is depleted of nucleotide by incubating with 10 mM EDTA containing buffer for 20 min at 30°C, washing twice with NP- HPS buffer, then re-suspended in the same buffer containing 1 mM EDTA/or 1 mM MgCl2, 1 mM DTT and 0.1% BSA. Cdc42 unbound sites are blocked by incubation of protein–bead complex for 15 min at RT. Thirty μL of this suspension is incubated with 20 mM inhibitor for 3 min at RT and added 30 μL of various concentrations of ice cold BODIPY-FL-GTP. Samples incubated at 4° C for 45 min and binding of fluorescent nucleotide to enzyme is measured using an Accuri flow cytometer. Raw data are exported and plotted using GraphPad Prism software. |
细胞实验 | Cells are incubated with 500 nM Calcein-AM and 1 µM PI for 15 min, after which live cells and dead cells (represented by positivity of Calcein-AM and PI staining, respectively) are counted utilizing the adherent cell Celigo™ cytometer. (Only for Reference) |
别名 | CID-2950007 |
分子量 | 407.49 |
分子式 | C22H21N3O3S |
CAS No. | 71203-35-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 40.8 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.454 mL | 12.2702 mL | 24.5405 mL | 61.3512 mL |
5 mM | 0.4908 mL | 2.454 mL | 4.9081 mL | 12.2702 mL | |
10 mM | 0.2454 mL | 1.227 mL | 2.454 mL | 6.1351 mL | |
20 mM | 0.1227 mL | 0.6135 mL | 1.227 mL | 3.0676 mL | |
50 mM | 0.0491 mL | 0.2454 mL | 0.4908 mL | 1.227 mL | |
100 mM | 0.0245 mL | 0.1227 mL | 0.2454 mL | 0.6135 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
ML141 71203-35-5 Apoptosis Cell Cycle/Checkpoint GPCR/G Protein MAPK CDK Ras inhibit toxicity cells CID-2950007 ML 141 ovarian noncompetitive CID 2950007 acute ML-141 anxiety allosteric CID2950007 cancer OVCA429 Inhibitor inhibitor